Video is loading...
Title: Newer drugs improve upon Gleevec for CML – CNL
Summary: MD Anderson researchers play crucial role in two New England Journal of Medicine studies showing newer drugs for chronic myeloid leukemia work faster and better than imatinib (Gleevec®).
Keywords: chronic myeloid leukemia, leukemia, Gleevec, Glivec, imatinib, dasatinib, Sprycel, nilotinib, Tasigna, Kantarjian, remission, cytogenetic, toxicity, Jorge Cortes, MD Anderson, CML, MD Anderson, Cancer, M.D. Anderson, M. D. Anderson